Here are three things to know:
1. CybroCell now comprises 36 U.S. and foreign issued patents with 40 pending.
2. The new patent involves differentiating human dermal fibroblast into chondrocyte-like cells by exposing them to a specific environment of growth factors, hypoxia, hydrostatic pressure and shear stress.
3. CybroCell is an off-the-shelf allogenic human dermal fibroblast product designed to treat degenerative disc disease.
More articles on biologics:
DiscGenics’ cell therapy passes safety review of first-in-human trial: 5 things to know
3 things to know about JRF Ortho
StemCyte gets FDA green light to continue studying spinal cord injury treatment stem cells: 5 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
